InvestSMART

Island Pharmaceuticals Limited (ASX:ILA)

ALERT: Price-sensitive ASX Announcement for ILA
Current share price for ILA : $0.415 0.06 (16.90%)+
Announcement
Release
17 Jun 2026 8:54AM
Price at Release
$0.355
Full Release
download
Summary
Island Pharmaceuticals Limited announced that the US FDA has granted Orphan Drug Designation to Galidesivir for the post-exposure prophylaxis of Marburg virus disease. This designation represents a significant regulatory milestone, providing potential benefits such as seven years of market exclusivity upon approval in the US, exemption from certain FDA fees, and regulatory support during development. The designation enhances the strategic and commercial position of the Galidesivir program, which is advancing under the FDA Animal Rule pathway. Recent progress includes securing agreements with US research institutes, manufacturing preparations, and upcoming dose optimization studies. Island Pharmaceuticals, trading as ASX:ILA, focuses on unmet needs in antiviral drugs for urgent viral and biosecurity threats.
Key Points
  • US FDA grants Orphan Drug Designation to Galidesivir for Marburg virus disease.
  • The designation provides seven years of US market exclusivity upon approval.
  • Exemption from certain FDA fees and regulatory support offered.
  • Galidesivir program is advancing under the FDA Animal Rule pathway.
  • Recent progress includes agreements with USAMRIID and manufacturing preparations.
  • Island Pharmaceuticals focuses on antiviral drugs for viral and biosecurity threats.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.